Evaluation of Clinical Interest of Anti-Aquaporin-4 Autoantibody Followup in Neuromyelitis Optica

Table 2

Relationship between anti-AQP4 Ab serum concentrations, complement-mediated cytotoxicity, and clinical parameters.

	Anti-AQP4 concentration (AU/mL)	P	Serum cytotoxicity (AU/mL)	P
Patients during a relapse	124 ± 127	𝑃=0.71	13.5 ± 12	𝑃=0.89
Patients during a remitting phase	176 ± 224		14.2 ± 11
Patients with the more severe impairment	94 ± 52	𝑃=0.38	10.2 ± 7.7	𝑃=0.21
Patients with the milder impairment	208 ± 248		17 ± 13

Anti-AQP4 Ab serum concentration and complement-mediated serum cytotoxicity were measured in 30 sera from 10 NMO patients with a cell-based assay as described in methods. We compared both biological parameters in samples taken in relapsing phase (<1 month after a relapse) versus remitting phase and in the 5 more disabled patients (i.e., with the highest EDSS scores) versus the other ones. P: alpha risk.